Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

5 clinical studies listed.

Filters:

Mucopolysaccharidosis I

Tundra lists 5 Mucopolysaccharidosis I clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT05619900

Registry of Patients Diagnosed With Lysosomal Storage Diseases

This is an international prospective and retrospective registry of patients with Lysosomal Storage Diseases (LSDs) to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with LSDs.

Gender: All

Ages: Any - 64 Years

Updated: 2026-04-08

1 state

Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis IV A
+5
RECRUITING

NCT06036693

MPS (RaDiCo Cohort) (RaDiCo-MPS)

The goal of this observational study is to characterize the epidemiology and natural history of MPS diseases by building a retrospective and prospective collection of extensive phenotypic data from French MPS patients.

Gender: All

Updated: 2026-02-11

Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis III
+5
ACTIVE NOT RECRUITING

NCT03153319

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.

Gender: All

Ages: 5 Years - Any

Updated: 2026-02-02

1 state

Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis VI
ENROLLING BY INVITATION

NCT06103487

Long Term Follow-Up for RGX-111

RGX-111-5101 is a long-term follow up study that evaluates the long term safety of RGX-111 in participants who have received RGX-111 (a gene therapy intended to deliver a functional copy of the alpha-L-iduronidase gene (IDUA) to the central nervous system) in a separate parent study.

Gender: All

Updated: 2024-07-03

2 states

Mucopolysaccharidosis I
ACTIVE NOT RECRUITING

NCT04628871

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.

Gender: All

Ages: 18 Years - Any

Updated: 2024-05-03

5 states

Hemophilia B
Mucopolysaccharidosis I
Mucopolysaccharidosis II